Combination of everolimus and exemestane improves survival for women with metastatic breast cancer

In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center.

Read the whole article on Physorg

More from Physorg